TIM-3 阻断：DIPG 的免疫和靶向治疗。
TIM-3 blockade: immune and targeted therapy in DIPG.
机构信息
Key Laboratory of Birth Defects and Related Diseases of Women and Children of MOE, State Key Laboratory of Biotherapy, West China Second University Hospital, Sichuan University, Chengdu, China.
Guangdong Institute of Gastroenterology, Department of General Surgery, Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
出版信息
Trends Mol Med. 2024 Feb;30(2):110-112. doi: 10.1016/j.molmed.2023.11.014. Epub 2023 Dec 12.
Diffuse intrinsic pontine glioma (DIPG) remains intractable to conventional treatments. While targeted therapy and immuno-oncology advances offer hope, few strategies show promising results. In a recent article in Cancer Cell, Ausejo-Mauleon et al. introduce TIM-3 blockade as a potential breakthrough for DIPG treatment by targeting cancer cells and regulating the immune microenvironment simultaneously.
弥漫性内在脑桥胶质瘤（DIPG）对常规治疗仍然难以控制。虽然靶向治疗和免疫肿瘤学的进展带来了希望，但很少有策略显示出有前途的结果。在最近发表在《癌细胞》杂志上的一篇文章中，Ausejo-Mauleon 等人介绍了 TIM-3 阻断作为 DIPG 治疗的潜在突破，通过同时靶向癌细胞和调节免疫微环境。
Zotero 插件